Abstracts tagged "Epidemiology"

Abstract Number: 0129 • ACR Convergence 2024
The Efficacy and Safety of Telitacicept Following Rituximab Immunotherapy on Antiphospholipid Syndrome, a Prospective 24- Week Study
Qiang Shu¹, Qing Zuraw², Xiaoyu Zhang³, Guillermo Pons-Estel⁴, Shuning Sun⁵, Qincheng Che¹, Xinyu Li⁶, Jie Li⁶ and Qi Liu⁶, ¹Qilu Hospital, Shandong Provincial Clinical Research Center for Immune Disease and Gout, Jinan, China; Qilu Hospital, Cheeloo College of Medicine, Shandong University, Rheumatology, Jinan, China, Jinan, China (People's Republic), ²RemeGen Biosciences, Inc., South San Francisco, China (People's Republic), ³Qilu Hospital, Shandong Provincial Clinical Research Center for Immune Disease and Gout, Jinan China, Beijing, China, ⁴Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina, ⁵Qilu Hospital, Shandong Provincial Clinical Research Center for Immune Disease and Gout, Jinan, China; Qilu Hospital, Cheeloo College of Medicine, Shandong University, Pheumatology, Jinan, China, Jinan, China (People's Republic), ⁶Qilu Hospital, Jinan, China (People's Republic)
Background/Purpose: Antiphospholipid syndrome (APS) is a challenging disease to treat and lack effective therapies. Rituximab (RTX) can deplete CD20+ peripheral B cells. Telitacicept (TA) is…
Abstract Number: 0161 • ACR Convergence 2024
Cross Country Burden of Osteoarthritis in Latin America and Caribbean from 1990-2021: A Comparative and Consistent Benchmarking Analysis for the Global Burden of Disease Study 2022
malay rathod¹, Eva Kalra², Rafael Sanchez-Dopazo,³, Janmay Vala⁴, Saif Syed⁵, Akhilesh Sharma⁶, Ashwinikumar Shandilya⁷, Asmita Gera⁸, Mohit Lakkimsetti⁹, Juhi Patel¹⁰, VISHRANT AMIN¹¹ and Hardik Desai¹², ¹Monmouth Medical Center, Rutgers University, Ewing, NJ, ²Trident Medical Cente, Charleston, SC, ³Larkin Community Hospital Palm Springs Campus, Hialeah, FL, ⁴Terna Medical College, Navi Mumbai, Maharashtra, India, ⁵Royal college of Surgeons,Dublin,Ireland, Dublin, Dublin, Ireland, ⁶Adesh Institute of Medical Sciences and Research, Bhatinda, India, ⁷Rural Medical college. Pravara institute of medical sciences., Ahmednagar, India, ⁸Tianjin medical University, Tianjin, China, Tianjin, Tianjin, China (People's Republic), ⁹Mamata Medical College,Khammam, Khammam, Telangana, India, ¹⁰GMERS MEDICAL COLLEGE VALSAD, 382330, Gujarat, India, ¹¹GMERS MEDICAL COLLEGE VALSAD, Ahmedabad, India, ¹²Gujarat Adani Institute of Medical Sciences, Bhuj, India
Background/Purpose: Osteoarthritis (OA) poses a significant and escalating health challenge across Latin America and the Caribbean (LAC), driven by demographic shifts, lifestyle factors, and varying…
Abstract Number: 0434 • ACR Convergence 2024
Pregnancy Outcomes of Biosimilars and Non-TNF Inhibitor Biologic Disease-Modifying Antirheumatic Drugs: A Scoping Review
Vienna Cheng¹, Neda Amiri², Vicki Cheng¹, Ursula Ellis³, Jacquelyn J. Cragg¹, Mark Harrison¹ and Mary A. De Vera¹, ¹University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ²University of British Columbia, Faculty of Medicine, Vancouver, BC, Canada, ³University of British Columbia, Woodward Library, Vancouver, BC, Canada
Background/Purpose: Biosimilar and biologic (b) DMARDs have revolutionized rheumatic disease management in the recent decades. As these drugs become introduced, it is important to understand…
Abstract Number: 0717 • ACR Convergence 2024
Associations Between Calendar Time and Age at Diagnosis with Mortality in a National Cohort of Veterans with ANCA-Associated Vasculitis from 2001-2020
Jennifer Hanberg¹, Svetlana Eden², Amy Anderson-Mellies², Suman Kundu², Matthew Freiberg², Zachary Wallace³ and Evelyn Hsieh⁴, and the Veterans Aging Cohort Study Project Team, ¹Brigham and Women's Hospital, Boston, MA, ²Vanderbilt University Medical Center and Tennessee Valley VA, Nashville, TN, ³Massachusetts General Hospital, Newton, MA, ⁴Yale School of Medicine / VA Connecticut Healthcare System, West Haven, Connecticut, New Haven, CT
Background/Purpose: It is not clear whether advances in ANCA-associated vasculitis (AAV) management between 2001-2020 have translated to improvement in population-level outcomes, including among older adults.…
Abstract Number: 0991 • ACR Convergence 2024
Comparing the Prevalence of Sarcoidosis in Canadian Rural, Urban, and Farming Populations
Varinder Hans¹, Don Voaklander¹, C. Allyson Jones² and Elaine Yacyshyn², ¹University of Alberta, Edmonton, Canada, ²University of Alberta, Edmonton, AB, Canada
Background/Purpose: Sarcoidosis is a granulomatous inflammatory response thought to be due to a dysregulated immune response to environmental antigens.1 The prevalence of sarcoidosis varies geographically.…
Abstract Number: 1095 • ACR Convergence 2024
The Incidence of Gout Among Individuals with Hyperuricemia over Time – an Insight from a Nationwide Cohort Study
Shay Brikman¹, Amir Bieber², Liel Serfaty, MA³, Ran Abuhasira, MD, PhD⁴, Nadav Rappoport⁵ and Naomi Schlesinger⁶, ¹Emek Medical Center, Afula, Israel, ²Emek Medical Center, Clalit Health Services, Raanana, Israel, ³Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be'er Sheva, Israel, ⁴Clinical Research Center, Soroka University Medical Center, Be'er Sheva, Israel, ⁵Ben-Gurion University of the Negev, Beer-Sheva, Israel, ⁶University of Utah, Salt Lake City, UT
Background/Purpose: Hyperuricemia is considered the most important risk factor for developing Gout, the most common adult inflammatory arthritis. Hyperuricemia is defined by a serum urate…
Abstract Number: 1353 • ACR Convergence 2024
Association Between Frailty and Incident Cancer in Newly Diagnosed Rheumatoid Arthritis
Bhavik Bansal¹, Laura Gold², Katherine Wysham³, James Andrews⁴, Alexa Meara⁵, Carolyn Presley⁶, Elad Sharon⁷, Jiha Lee⁸, Jennifer Barton⁹, Una Makris¹⁰ and Namrata Singh¹¹, ¹All India Institute of Medical Sciences, New Delhi, Delhi, India, ²University of Washington, Seattle, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵The Ohio State University Wexner Medical Center, COLUMBUS, OH, ⁶The Ohio State Medical Center, Columbus, OH, ⁷Dana Farber Cancer Institute, Boston, MA, ⁸University of Michigan, Ann Arbor, MI, ⁹VA Portland Health Care System/OHSU, Portland, OR, ¹⁰UT Southwestern Medical Center and Dallas VA, Dallas, TX, ¹¹University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid Arthritis (RA) is associated with an increased risk of cancer, but the underlying risk factors remain poorly understood. Frailty is linked to an…
Abstract Number: 1756 • ACR Convergence 2024
What Is the Impact of Prior TNF Inhibitor Treatment on the Time to Achieve Low Disease Activity and the Durability of Low Disease Activity? Real-world Results Based on 17 858 European Patients with Axial Spondyloarthritis Initiating a TNF Inhibitor or an IL-17A Inhibitor
Jette Heberg¹, Stylianos Georgiadis², Marion Pons³, Anne Gitte Loft⁴, Brigitte Michelsen⁵, Louise Linde³, Daniela DiGuiseppe⁶, Simon Horskjær Rasmussen³, Mehrdad Kazemi³, Gary Macfarlane⁷, Gareth Jones⁷, Karin Laas⁸, Sigrid Vorobjov⁹, Isabel Castrejon¹⁰, Ziga Rotar¹¹, Katja Perdan-Pikmajer¹¹, Ladislav Šenolt¹², Jana Baranová¹³, Bente Glintborg¹⁴, Adrian Ciurea¹⁵, Miguel Bernardes¹⁶, Paula Valente¹⁷, Bjorn Gudbjornsson¹⁸, Gerdur Gröndal¹⁸, Gunnstein Bakland¹⁹, Catalin Codreanu²⁰, Corina Mogosan²⁰, Florenzo Iannone²¹, Roberto Caporali²², Johan Karlsson Wallman²³, Vappu Rantalaiho²⁴, Ritva Peltomaa²⁵, Karel Pavelka²⁶, Pavel Horak²⁷, Diogo Esperança Almeida²⁸, Sara Dias Rodrigues²⁹, Lykke Oernbjerg², Mikkel Ostergaard³⁰ and Merete Hetland³¹, ¹Rigshospitalet Glostrup, København V, Denmark, ²Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ³Rigshospitalet Glostrup, Glostrup, Denmark, ⁴Aarhus University Hospital and Aarhus University, Horsens, Denmark, ⁵Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, ⁶Karolinska Institutet, Stockholm, ⁷University of Aberdeen, Aberdeen, United Kingdom, ⁸East-Tallinn Central Hospital, Tallinn, Estonia, ⁹National Institute for Health Development, Tallinn, Estonia, ¹⁰Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain, ¹¹University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹³Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, ¹⁴DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ¹⁵University Hospital Zurich, Zürich, Switzerland, ¹⁶São João Hospital Center and FMUP, Lisboa, Portugal, ¹⁷Rheumatology Department, Hospital de São Sebastião, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal, ¹⁸Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹⁹Department of Rheumatology, University Hospital North Norway, Tromsø, Norway, ²⁰University of Medicine and Pharmacy, Bucharest, Romania, ²¹Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ²²Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ²³Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, ²⁴Tampere University Hospital, Tampere University and Kanta-Häme Central Hospital, Tampere, Finland, ²⁵Helsinki University Hospital and University of Helsinki, Helsinki, Finland, ²⁶Institute of Rheumatology and Charles University, Praha, Czech Republic, ²⁷3rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic, ²⁸Hospital de Braga, Braga, Portugal, ²⁹Serviço de Reumatologia, Hospital Egas Moniz, Unidade Local de Saúde Lisboa Ocidental, Lisboa, Portugal, ³⁰Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ³¹Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) and Interleukin-17Ai inhibitors (IL-17Ai) have shown effectiveness in achieving low disease activity (LDA) in patients with axial spondyloarthritis (axSpA).…
Abstract Number: 1893 • ACR Convergence 2024
Hydroxychloroquine Use in Early Pregnancy and Risk of Preterm Delivery in a Californian Cohort of Lupus Pregnancy
Amadeia Rector¹, Emily Liu², Miranda Cantu³, Eliza Chakravarty⁴, Maurice Druzin⁵, Gary Shaw⁶, Michael Weisman⁷, Monique Hedderson² and Julia Simard⁸, ¹Stanford University, San Francisco, CA, ²Kaiser Permanente Division of Research, Oakland, CA, ³Patient partner, Portage, MI, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Stanford University School of Medicine, Stanford, CA, ⁶Stanford University School of Medicine, Stanford, ⁷Stanford University, Los Angeles, CA, ⁸Stanford School of Medicine, Stanford, CA
Background/Purpose: Preterm delivery (PTD) occurs 2-3 times more frequently in patients with systemic lupus erythematosus (SLE) compared to the general obstetric population. Hydroxychloroquine (HCQ), a…
Abstract Number: 2055 • ACR Convergence 2024
Demographic and Ocular Characteristics of Scleritis Patients with Systemic Rheumatologic Disease in the IRIS® Registry (Intelligent Research in Sight)
Laura Kopplin¹ and Karen Armbrust², ¹Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, ²Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN
Background/Purpose: Scleritis is a rare, potentially vision threatening ocular inflammatory disease. 30-40% of scleritis is associated with systemic autoimmune diseases with reports of worse visual…
Abstract Number: 2489 • ACR Convergence 2024
Avacopan for Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) in a Real-World Setting
Naomi Patel¹, Ana Fernandes¹, Andrew King¹, Shruthi Srivatsan¹, Colebrook Johnson¹, Zachary Williams¹, Madison Negron¹, Caleb Bolden¹, Miao Lin¹, Bohang Jiang¹, Sam Oh², Darcy Trimpe², Sushmitha Inguva² and Zachary Wallace³, ¹Massachusetts General Hospital, Boston, MA, ²Amgen Inc., Thousand Oaks, CA, ³Massachusetts General Hospital, Newton, MA
Background/Purpose: Avacopan is approved in the US for use in adults with severe active GPA or MPA alongside background immunosuppression. Efficacy and safety data on…
Abstract Number: 2681 • ACR Convergence 2024
Association of Social Determinants of Health with Systemic Lupus Erythematosus in the United States: Nationally Representative Estimates for 2017-2021
Ami Vyas, Steven Cohen and Christine Eisenhower, University of Rhode Island, Kingston, RI
Background/Purpose: Careful assessment of individuals’ social determinants of health (SDOH) that affect systemic lupus erythematosus (SLE) is crucial, as such evidence will improve care and…
Abstract Number: 0126 • ACR Convergence 2023
Epidemiology and Retrospective Case-Control Analysis of IIM in the US Veteran Population
Vladimir Liarski, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic Inflammatory Myopathy (IIM) - comprising polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM) - is rare and difficult to study. We sought…
Abstract Number: 0299 • ACR Convergence 2023
Trends and Outcomes of Hospitalized Patients with Idiopathic Inflammatory Myopathy and Venous Thromboembolism: A Nationwide Inpatient Sample Analysis from US (2016-2019)
Haseeb Chaudhary¹, Biraj Shrestha², Sarah Abi Doumeth³ and Maya Mattar⁴, ¹Case Western Reserve University, Westlake, OH, ²Tower Health System, Reading, PA, ³Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, ⁴Louis Stokes VA Medical Center, Cleveland, OH
Background/Purpose: Recent evidence suggests increased prevalence of venous thromboembolism (VTE) in patients with idiopathic inflammatory myopathies (IIM). The literature on the clinical implications of VTE…
Abstract Number: 0618 • ACR Convergence 2023
Incident versus Prevalent Interstitial Lung Disease in Systemic Sclerosis in the EUSTAR Database: Different Disease Phenotypes and Prognosis
liubov Petelytska¹, Arthiha Velauthapillai², Lorenzo Tofani³, Patricia Carreira⁴, Giovanna Cuomo⁵, Eric Hachulla⁶, Ivan Castellvi⁷, Radim Becvar⁸, Alexandra Balbir-Gurman⁹, Paolo Airò¹⁰, Irena Litinsky¹¹, Lesley Ann Saketkoo¹², Madelon Vonk¹³, Jeska de Vries-Bouwstra¹⁴, Anna Maria Hoffmann-Vold¹⁵, marco Matucci Cerinic¹⁶, Oliver Distler¹⁷ and Cosimo Bruni¹⁷, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Department of Statistics, Computer Science, Applications, University of Florence, Florence, Italy, ⁴Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵Department of Precision Medicine, “Luigi Vanvitelli” University of Campania, Naples, Italy, ⁶University of Lille, Lille, France, ⁷Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ⁸Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Praha, Czech Republic, ⁹Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ¹⁰Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, ¹¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ¹²University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, ¹³Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁴Leiden University Medical Center, Leiden, Netherlands, ¹⁵Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ¹⁶Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Although 50% of patients with systemic sclerosis (SSc) present with interstitial lung disease (ILD) at baseline, new onset of ILD can also occur later…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].